While there is no direct chemical interaction between the two, the primary goal is to manage the way they both affect your bodys fluid and blood pressure levels
A benefits strategy that says no to medication without providing a credible, evidence-based alternative can create frustration, perceived inequity, and disengagement
Cardiovascular outcome studies Although multiple clinical trials evaluating cardiovascular events associated with GLP-1 RA use as the primary outcome are currently ongoing (Table 1), abundant non-primary outcome data are available from many clinical trials on the efficacy of GLP-1 RAs marketed earlier, such as exenatide (DURATION studies) and liraglutide (LEAD studies)
and healthy inside and out
More evidence is needed to know whether its directly caused by the medication
Objective In this narrative overview, the following selection criteria were used: Inclusion criteria included (a) journal reports and/or reviews of clinical studies using pre-, peri-, or postmenopausal women in combination(s) with collagen, hyaluronic acid, curcumin, glutathione, and estrogen deficiency and (b) articles from 2020 to 2025